UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~June~~August 38, 2025

Akero Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-38944

81-5266573

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

601 Gateway Boulevard, Suite 350

South San Francisco, CA

94080

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code (650) 487-6488

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		~~Tradingsymbol~~Trading symbol(s)		Name of each ~~exchangeon~~exchange on which registered
Common Stock, par value $0.0001 per share		AKRO		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 52.~~07.~~02 ~~Submission~~Results of ~~Matters~~Operations toand aFinancial ~~Vote of Security Holders~~Condition.

~~Akero~~On ~~Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June~~August 38, 2025~~. As of April 10~~, ~~2025,~~Akero ~~the record date for the Annual Meeting~~Therapeutics, ~~there were 79,679,222 outstanding shares of the Company’s common stock~~Inc. ~~The~~announced ~~Company’s~~its ~~stockholders~~financial ~~voted~~results onfor the ~~following~~quarter ~~matters,~~ended ~~which are described in detail in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission (“SEC”) on April~~June 2830, 2025~~: (i) to elect two directors, Judy Chou, Ph~~.D. ~~and~~A ~~Tomas~~copy ~~Heyman, as Class III directors~~ of the ~~Company~~press torelease ~~each~~is ~~serve~~being ~~for~~furnished aas ~~three-year~~Exhibit term expiring at the Company’s annual meeting of stockholders in 2028 and until their respective successors have been duly elected and qualified, subject to their earlier death, resignation or removal (“Proposal 99.1~~”),~~ ~~(ii)~~ to ~~ratify~~this ~~the~~Current ~~appointment~~Report ofon ~~Deloitte &~~Form ~~Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 (“Proposal 2”) and (iii) to approve, by non~~8-~~binding advisory vote, the compensation of the Company’s named executive officers (“Proposal 3”)~~K.

The ~~Company’s~~information ~~stockholders~~in ~~approved~~this ~~the~~Current ~~Class III~~Report ~~director~~on ~~nominees~~Form ~~recommended~~8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for ~~election~~purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in ~~Proposal~~any 1filing atunder the ~~Annual~~Securities ~~Meeting.~~Act ~~The~~of ~~Company’s~~1933 ~~stockholders~~or ~~voted~~the ~~for~~Exchange ~~Class III~~Act, ~~directors~~except as ~~follows:~~expressly set forth by specific reference in such filing.

Class III Director Nominee	For		Withheld		Broker Non-Votes
Judy Chou, Ph.D.		46,654,444		15,405,899		5,333,604
Tomas Heyman		28,017,151		34,043,192		5,333,604

Item 9.01

Financial Statements and Exhibits.

~~The~~(d) ~~Company’s~~Exhibits ~~stockholders approved to ratify the appointment of Deloitte & Touche LLP in Proposal 2. The votes cast at the Annual Meeting were as follows:~~

For	Against	Abstain	Broker Non-Votes
Exhibit No.	Description
67,325,603	38,564	29,780	0
99.1	Press release issued by Akero Therapeutics, Inc. on August 8, 2025, furnished herewith.
104	Cover Page Interactive Data File

~~The~~SIGNATURES ~~Company’s stockholders approved, by non-binding advisory vote, the compensation of the Company’s named executive officers in Proposal 3. The votes cast at the Annual Meeting were as follows:~~

For		Against		Abstain		Broker Non-Votes
60,698,263		1,199,541		162,539		5,333,604

No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.

* * *

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 4, 2025	AKERO THERAPEUTICS, INC.
Date: August 8, 2025	AKERO THERAPEUTICS, INC.
	By:	/s/ Andrew Cheng
		Andrew Cheng, M.D., Ph.D.
	Name:	Andrew Cheng, M.D., Ph.D.
		President and Chief Executive Officer
	Title:	President and Chief Executive Officer

Filing Compare · Akero Therapeutics, Inc.